When a university spinout is formed, the first equity decision a technology transfer office (TTO) and its academic founders make is not how ownership will change over time — that is the subject of dilution mechanics, anti-dilution provisions, and pro-rata rights covered in Equity Dilution for Academic Founders — it is the starting cap table itself: what percentage does the university take in exchange for its exclusive license, what percentage do the founding academics hold, and how is that founder allocation divided if there is more than one inventor or a non-academic co-founder involved. This guide covers that formation-stage decision: what actually drives the split, the ranges institutions and sector benchmarks currently use, how founder-vs-founder allocation and vesting work, and how the deal gets negotiated in practice.
What the “equity split” actually refers to
A university spinout is typically formed around an exclusive license (or an option to one) from the university’s technology transfer office to a newly incorporated company. Rather than, or in addition to, charging that company a cash license fee and ongoing royalties, the university takes an ownership stake — ordinary shares in the new company — as part or all of its consideration for the license. The “equity split” is the percentage of the company’s founding share capital allocated to the university versus the percentage allocated to the founder(s), decided once, at incorporation, before any external investment has come in.
This is distinct from three related but separate questions:
- Dilution across funding rounds — how both stakes shrink proportionally as the company raises seed, Series A, and later capital. See Equity Dilution for Academic Founders for that mechanics.
- Royalty vs. equity as a compensation structure — whether the university takes equity at all, versus a running royalty on product sales, versus a hybrid of both. See Royalty vs. Equity Licensing Compensation for that comparison.
- Funding the company once formed — grants, gap funds, SBIR/STTR, or venture capital used to actually capitalize the business. See Funding Options for a University Spinout.
What drives the initial percentage
There is no single “correct” split — the percentage that ends up in the incorporation documents is the product of several negotiated factors, and institutional policy increasingly sets a starting benchmark rather than leaving each deal to be negotiated from scratch:
- How IP-intensive the sector is. A therapeutics or deep-tech spinout is usually built around a small number of patented, university-owned inventions that are difficult for the company to work around — the university’s contribution to enterprise value is large and durable, which supports a larger equity stake. A software spinout is typically built more around the founders’ ongoing technical execution than around a defensible patent estate — the university’s founding contribution is proportionally smaller, and taking a large equity stake risks under-incentivizing the people who actually have to build the product. This IP-intensity distinction is the single biggest driver across current UK sector guidance (see below) and is a reasonable frame for any institution setting policy, not just a UK-specific rule.
- How much value is captured via equity versus royalty versus a hybrid. A university that takes a smaller equity stake alongside a running royalty on future product sales is spreading its return across two mechanisms instead of one; a university that takes equity only, with no royalty, typically negotiates for a larger stake to compensate. See Royalty vs. Equity Licensing Compensation for how institutions reason through that trade-off.
- Stage of the technology. An invention that is still early-stage (low Technology Readiness Level) and needs significant further development inside the company generally supports a lower founding stake for the university and a correspondingly larger allocation to the founders who will do that development work, versus a technology that is already close to market-ready at spinout.
- Institutional policy versus case-by-case negotiation. Some TTOs publish a fixed or presumptive split that applies to most spinouts in a given category (see the Southampton example below); others negotiate each deal individually against internal guidelines. A published, predictable policy is increasingly treated as best practice because it removes a major source of delay and uncertainty for founders and outside investors.
- Investor expectations. Where an investor is involved at or shortly after formation, the university’s founding stake is scrutinized as part of diligence — an unusually large university stake can itself be a deterrent to institutional investment, because it reduces the pool available to incentivize management and future hires.
Typical ranges: what current sector guidance actually says
The most concrete, publicly documented benchmarks for spinout equity splits currently come from the UK, where both individual universities and a sector-wide standardization effort have published specific numbers. These are real, sourced figures — not a universal rule for every institution or jurisdiction — but they are the clearest available reference point for what “typical” currently means in practice.
- TenU’s University Spin-out Investment Terms (USIT) Guide (first published 2023, updated since), developed jointly by a group of leading UK research-intensive university TTOs together with venture investors, recommends university equity stakes of roughly 10-25% for IP-intensive sectors such as life sciences, and 10% or less for less IP-intensive spinouts, particularly software, with founders holding the remainder. The guide is explicitly framed as a benchmark deal template — covering equity, board rights, and other founding terms — intended to reduce case-by-case negotiation.
- The UK Government’s Independent Review of University Spin-out Companies (published November 2023, co-chaired by the Vice-Chancellor of the University of Oxford, all 11 of its recommendations accepted by government) recommended broadly the same ranges as a working standard: up to around 25% university equity for spinouts leaning heavily on university IP, and 10% or less for less IP-intensive spinouts, and specifically recommended the USIT Guide as the template UK institutions should adopt for deal negotiation, including equity splits, to accelerate standardization across the sector.
- University of Southampton’s Spinout Equity Guide (in effect from 31 May 2024) is a concrete example of an institution adopting a published, presumptive split: 90% founder / 10% university for knowledge-intensive spinouts, and 95% founder / 5% university for software spinouts. This represented a significant reduction from Southampton’s prior decade-long practice of taking roughly a third of the founding equity. Southampton’s guide also specifies that the university’s founding shares carry no anti-dilution protection — the university’s stake dilutes on the same terms as the founders’ as external investment comes in, which is a meaningful detail distinct from the across-rounds anti-dilution provisions covered in the companion guide on dilution.
Outside the UK, published, institution-specific splits are far less commonly disclosed, and practice varies more by individual negotiation than by a stated policy. US research administrators should treat the UK figures above as a directional benchmark for how sector and IP-intensity shape a split, not as a number to import directly — always confirm current policy directly with your own institution’s TTO, since equity-versus-royalty balance, standard license terms, and typical founding stakes differ by institution and are updated periodically.
Equity as part of the license, not separate from it
The founding equity stake is not a standalone grant — it is consideration the university receives, usually under the same exclusive license agreement (or an option to one) that gives the spinout the right to develop and commercialize the underlying invention. A TTO negotiating the initial split is typically negotiating it alongside, and sometimes in place of, other license consideration: an upfront license fee, ongoing royalties on net sales, and milestone payments tied to development or regulatory progress. A larger equity stake is frequently paired with a lower royalty rate, and vice versa, because both mechanisms exist to let the university share in the value it helped create. See Royalty vs. Equity Licensing Compensation for a direct comparison of how those two mechanisms trade off, and what drives an institution toward one, the other, or a hybrid.
Splitting the founder side: multiple inventors and non-academic co-founders
The university’s stake is only half the initial cap table. The founder-side percentage then has to be divided among however many people are joining as founders, which raises questions the university’s licensing team is not typically the deciding party on, but that a research administrator should expect to see surface:
- Multiple academic co-inventors. Where a patent or invention disclosure lists several university researchers as inventors, their relative founder allocation is a separate negotiation from inventorship credit on the patent itself — being a named inventor does not automatically entitle someone to an equal (or any) founder equity share if they are not going to be an active operating founder of the company. Institutions increasingly separate “inventor” (a patent-law and Bayh-Dole determination) from “founder” (a role in the operating company) explicitly for this reason.
- A non-academic CEO or business co-founder. Many spinouts bring in an outside CEO, commercial lead, or co-founder who was not part of the original research and is not a university employee. That person’s equity typically comes out of the overall founder pool (not the university’s stake), and is a common source of tension precisely because it dilutes the academic founders’ share before any external investor is even involved.
- Faculty conflict-of-interest review. Because faculty founders are simultaneously university employees and company equity holders, most institutions require a formal conflict-of-interest disclosure and management plan before or alongside finalizing the equity split — see Faculty Conflict of Interest in Startups for how that review typically works and what it covers.
Vesting on founder shares at formation
Even though the initial split sets each party’s target percentage, it is increasingly standard investor and TTO practice for founder shares to be subject to time-based vesting (commonly a schedule on the order of several years with an initial cliff, similar to standard startup practice generally) rather than being fully owned outright from day one. The rationale is straightforward: if a founder leaves the company early, unvested shares typically return to the company’s option pool (or, depending on the agreement, are reallocated) rather than being retained in full by a departed founder — protecting the remaining team and future investors from a large equity block held by someone no longer contributing. Whether and how founder vesting is structured is set out in the company’s articles/shareholders’ agreement at formation, and institutions vary in how prescriptive their standard templates are about it; it is a distinct question from whether the university’s own shares carry anti-dilution protection (most published guidance, including Southampton’s, gives the university’s founding shares no special anti-dilution treatment — see above).
How the split actually gets negotiated
In practice, the initial split is set through a combination of institutional policy and deal-specific negotiation between the TTO’s licensing team, the founders (often advised by outside counsel once the deal reaches term-sheet stage), and, where an investor is involved at formation, that investor’s own diligence expectations. Sector standardization efforts such as the USIT Guide exist specifically to reduce how much of this has to be negotiated from a blank page each time — an institution that has adopted or aligned with a published benchmark can move a spinout from disclosure to incorporation considerably faster than one negotiating bespoke terms every time. Research administrators supporting a spinout in formation should expect the process to touch: the underlying exclusive license terms (equity, royalty, or hybrid), the university’s founding share percentage and whether it carries anti-dilution rights, the founder pool allocation and vesting, and a conflict-of-interest sign-off for any faculty founder. Once those are set, the company can incorporate and the next stage — securing initial funding and, eventually, raising outside capital — begins; see Funding Options for a University Spinout and Entrepreneurial Resources for University Spinouts and Faculty Founders for what typically comes next, and Equity Dilution for Academic Founders for how the split negotiated here changes as that funding comes in.
Frequently asked questions
What percentage equity does a university typically take in a spinout?
There is no universal figure, but current UK sector benchmarks (the TenU USIT Guide and the government-commissioned Independent Review of University Spin-out Companies) converge on roughly 10-25% for IP-intensive sectors like life sciences, and 10% or less — often 5-10% — for less IP-intensive sectors like software. Individual institutions publish their own presumptive splits; the University of Southampton, for example, uses 10% (knowledge-intensive) or 5% (software), with founders holding the remainder. Always confirm your own institution’s current policy directly with its TTO rather than assuming a benchmark figure applies.
Is the university’s equity stake the same as royalties on the license?
No. Equity and royalties are two different mechanisms by which a university can capture value from a license, and are often combined. See Royalty vs. Equity Licensing Compensation for how institutions decide between them.
Does the university’s founding equity get diluted the same way as the founders’?
In most current published guidance, yes — the university typically holds ordinary shares with no special anti-dilution protection, meaning its percentage shrinks proportionally alongside the founders’ as the company raises outside investment. That across-rounds mechanic is covered in detail in Equity Dilution for Academic Founders.
Do all academic co-inventors automatically get an equal founder equity share?
No. Being listed as an inventor on the underlying patent or invention disclosure is a separate determination from being allocated founder equity — the latter is negotiated based on who is actually taking an active operating role in the company, and institutions increasingly treat the two as distinct decisions.
Is founder equity subject to vesting the same way investor-issued equity is?
Increasingly, yes — many spinouts apply a standard time-based vesting schedule to founder shares from formation, so that a founder who departs early does not retain their full allocation. The specific schedule is set in the company’s founding documents and varies by institution and investor expectations.
